NEWS & EVENTS

Latest news and upcoming events

Ysios Capital ESG Report
20 Nov 2024

Ysios Capital ESG Report

Upcoming events

  • AI in Drug Discovery and Biomedicine
    31 March 2025
    Barcelona

    download

  • Redefining Early Stage of Investment (RESI)
    1 April 2025
    Barcelona

    download

  • Life Sciences Conference – Van Lanschot Kempen
    2 - 3 April 2025
    Amsterdam

    download

  • Swisss Biotech Day
    5 - 6 May 2025
    Basel

    download
NorthSea Therapeutics Announces Publication of Positive Results from Phase 2b ICONA Clinical Trial of Icosabutate in Biopsy-Confirmed F1-F3 MASH in Journal of Hepatology<
06 Mar 2025

NorthSea Therapeutics Announces Publication of Positive Results from Phase 2b ICONA Clinical Trial of Icosabutate in Biopsy-Confirmed F1-F3 MASH in Journal of Hepatology

Positive results support advancement of icosabutate into further clinical development in MASH patients
MedLumics® Announces the Publication of FIM Results for the AblaView® (PF) Ablation System in (AF) Patients, Including Clinical Safety and Our Ability to Predict Durable Lesions at 3 Months With 100% Specificity<
05 Mar 2025

MedLumics® Announces the Publication of FIM Results for the AblaView® (PF) Ablation System in (AF) Patients, Including Clinical Safety and Our Ability to Predict Durable Lesions at 3 Months With 100% Specificity

Significant advancement toward more precise, safer, and more effective treatments for patients.
Minoryx announces dosing of the first patient with leriglitazone in the phase 2a study in Rett’s Syndrome (TREE study)<
05 Mar 2025

Minoryx announces dosing of the first patient with leriglitazone in the phase 2a study in Rett’s Syndrome (TREE study)

The results from the TREE study are expected during the first half of 2026
SparingVision appoints Anjeza Gjino as Chief Financial Officer<
03 Mar 2025

SparingVision appoints Anjeza Gjino as Chief Financial Officer

Anjeza’s proven track-record and experience in scaling-up and financing biotech companies will be invaluable to SparingVision.
Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02<
26 Feb 2025

Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02

Proceeds will be used to support the advancement of multiple first-in-class ADC programs into the clinic and through clinical proof of concept
Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy<
20 Feb 2025

Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy

The Phase 3 EPIC trial is a randomized, sham-controlled, double-blind study evaluating NRTX-1001 cell therapy in adults with drug-resistant mesial temporal lobe epilepsy
NorthSea Therapeutics Announces Expansion of Leadership Team with Key Industry Veteran Hires<
20 Feb 2025

NorthSea Therapeutics Announces Expansion of Leadership Team with Key Industry Veteran Hires

Topline data from SEFA-1024 Phase 2a clinical trial in SHTG expected in 3Q 2025
Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into Clinical Development Across Cancer Types<
19 Feb 2025

Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into Clinical Development Across Cancer Types

Accelerating development of first-in-class ADCs in multiple large solid tumor types designed against novel targets with a focus on eliminating hard-to-treat resistant cancer cells
Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria<
04 Feb 2025

Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria

Continues to anticipate announcing topline data from Explore-CKD trial in Q2 2025
SparingVision advances PRODYGY trial into Phase II following positive DSMB recommendation<
21 Jan 2025

SparingVision advances PRODYGY trial into Phase II following positive DSMB recommendation

DSMB confirms favorable safety profile of SPVN06 across all three doses in patients with severe advanced rod-cone dystrophy (RCD)(n=9)

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

rabbywallet offers a seamless, secure solution for managing digital assets. With its intuitive design, it ensures fast transactions and robust security for all your cryptocurrency needs.